Literature DB >> 1826594

Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon.

D N Gilbert1, C A Wood, R C Kimbrough.   

Abstract

Patients with blood cultures positive for gram-positive cocci were enrolled in a prospective randomized double-blind comparative trial of vancomycin at 15 mg/kg every 12 h versus teicoplanin at 6 mg/kg every 12 h for three doses and then 6 mg/kg every 24 h. A total of 54 patients were randomized, and 40 were evaluable. Of the 40, 9 had infection of indwelling vascular catheters. Four infections were due to Staphylococcus aureus, and five were due to Staphylococcus epidermidis. In concert with catheter removal, all patients were treated successfully, regardless of which drug they were taking. Of 31 patients without an indwelling catheter, 19 were infected with S. aureus, and 12 of the 19 had either endocarditis or mycotic aneurysm. Six of eight patients given teicoplanin failed treatment, as opposed to one of four patients given vancomycin (P = 0.14). Of greater concern, four of four patients with left-sided endocarditis or mycotic aneurysm failed to recover when given teicoplanin, as opposed to one of three patients given vancomycin (P = 0.07). Although not quite statistically significant, the unexpectedly high number of treatment failures with teicoplanin resulted in a decision to discontinue patient enrollment. It is suggested that future trials explore the efficacy of larger doses of teicoplanin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1826594      PMCID: PMC244945          DOI: 10.1128/AAC.35.1.79

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis.

Authors:  H F Chambers; S Kennedy
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

2.  Staphylococcus aureus bacteremia during therapy.

Authors:  R H Eng; E Bishburg; S M Smith; P Scadutto
Journal:  J Infect Dis       Date:  1987-06       Impact factor: 5.226

3.  In vitro activity and human pharmacokinetics of teicoplanin.

Authors:  L Verbist; B Tjandramaga; B Hendrickx; A Van Hecken; P Van Melle; R Verbesselt; J Verhaegen; P J De Schepper
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

4.  Comparative pharmacokinetics and pharmacodynamics of amikacin and ceftazidime in tricuspid and aortic vegetations in experimental Pseudomonas endocarditis.

Authors:  A S Bayer; D J Crowell; J Yih; D W Bradley; D C Norman
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

5.  Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center.

Authors:  D P Levine; R D Cushing; J Jui; W J Brown
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

6.  Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy.

Authors:  H F Chambers; R T Miller; M D Newman
Journal:  Ann Intern Med       Date:  1988-10-15       Impact factor: 25.391

7.  Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients.

Authors:  C Leport; C Perronne; P Massip; P Canton; P Leclercq; E Bernard; P Lutun; J J Garaud; J L Vilde
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

8.  Teicoplanin in the treatment of infections by staphylococci, Clostridium difficile and other gram-positive bacteria.

Authors:  F de Lalla; D Santoro; E Rinaldi; F Suter; M Cruciani; M H Guaglianone; G Rizzardini; G Pellegata
Journal:  J Antimicrob Chemother       Date:  1989-01       Impact factor: 5.790

9.  Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography.

Authors:  A C Cremieux; B Maziere; J M Vallois; M Ottaviani; A Azancot; H Raffoul; A Bouvet; J J Pocidalo; C Carbon
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

10.  Teicoplanin, its pharmacokinetics, blister and peritoneal fluid penetration.

Authors:  R Wise; I A Donovan; C A McNulty; R Waldron; J M Andrews
Journal:  J Hosp Infect       Date:  1986-03       Impact factor: 3.926

View more
  26 in total

1.  Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis.

Authors:  Juliette Pavie; Agnès Lefort; Marie-Cécile Ploy; Laurent Massias; Françoise Chau; Louis Garry; François Denis; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

Review 2.  Pharmacokinetic and pharmacodynamic requirements for antibiotic therapy of experimental endocarditis.

Authors:  A C Cremieux; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

3.  Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design.

Authors:  Konstantinos Z Vardakas; Michael N Mavros; Nikolaos Roussos; Matthew E Falagas
Journal:  Mayo Clin Proc       Date:  2012-04       Impact factor: 7.616

Review 4.  Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.

Authors:  C M Spencer; H M Bryson
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

5.  Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.

Authors:  H H Houlihan; R C Mercier; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

6.  A comparison of different antibiotic regimens for the treatment of infective endocarditis.

Authors:  Arturo J Martí-Carvajal; Mark Dayer; Lucieni O Conterno; Alejandro G Gonzalez Garay; Cristina Elena Martí-Amarista
Journal:  Cochrane Database Syst Rev       Date:  2020-05-14

Review 7.  A risk-benefit assessment of teicoplanin in the treatment of infections.

Authors:  F de Lalla; A Tramarin
Journal:  Drug Saf       Date:  1995-11       Impact factor: 5.606

8.  Efficacy of temafloxacin in experimental Streptococcus adjacens endocarditis and autoradiographic diffusion pattern of [14C]temafloxacin in cardiac vegetations.

Authors:  A C Cremieux; A Saleh-Mghir; J M Vallois; B Maziere; M Muffat-Joly; C Devine; A Bouvet; J J Pocidalo; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

Review 9.  Teicoplanin: 10 years of clinical experience.

Authors:  M Trautmann; H Wiedeck; M Ruhnke; M Oethinger; R Marre
Journal:  Infection       Date:  1994 Nov-Dec       Impact factor: 3.553

Review 10.  Anti-infective treatment in intensive care: the role of glycopeptides.

Authors:  R N Grüneberg; A P Wilson
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.